{"transactions":[{"id":674882,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-26T22:08:21.000Z","date":"2026-08-24","kind":"grant","planned":false,"acquired":true,"shares":5800051,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":5800051,"derivative":{"exercise_price":0.175,"expiration_date":"2036-08-23","underlying":"Common Stock","underlying_shares":5800051},"source":{"system":"sec-edgar","filing":"0001352620-26-000006","document":"wk-form4_1787782098.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000006/wk-form4_1787782098.xml","form_type":"4"}},{"id":674881,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Pre-Funded Warrant (Right to Buy)","published_at":"2026-08-26T22:08:21.000Z","date":"2026-08-24","kind":"grant","planned":false,"acquired":true,"shares":166,"price":999.999,"value":165999.834,"ownership":{"direct":false,"nature":"By Family Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of Series A-1 non-voting convertible preferred stock is convertible automatically upon receipt of stockholder approval under applicable Nasdaq rules and regulations in connection with the Issuer's private placement pursuant to which the Pre-Funded Warrants were issued (\"Stockholder Approval\") into a number of shares of the Issuer's common stock equal to $1,000 divided by $0.14, pursuant to the terms of the Series A-1 Certificate of Designation and subject to applicable beneficial ownership limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrant has no expiration date and is exercisable immediately. Prior to the Issuer obtaining Stockholder Approval, the Pre-Funded Warrants are only exercisable for shares of Series A-1 non-voting convertible preferred stock. Following the Issuer's receipt of Stockholder Approval, the Pre-Funded Warrants are only exercisable for shares of the Issuer's common stock."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each share of Series A-1 non-voting convertible preferred stock is convertible automatically upon receipt of stockholder approval under applicable Nasdaq rules and regulations in connection with the Issuer's private placement pursuant to which the Pre-Funded Warrants were issued (\"Stockholder Approval\") into a number of shares of the Issuer's common stock equal to $1,000 divided by $0.14, pursuant to the terms of the Series A-1 Certificate of Designation and subject to applicable beneficial ownership limitations."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series A-1 non-voting convertible preferred stock is convertible automatically upon receipt of stockholder approval under applicable Nasdaq rules and regulations in connection with the Issuer's private placement pursuant to which the Pre-Funded Warrants were issued (\"Stockholder Approval\") into a number of shares of the Issuer's common stock equal to $1,000 divided by $0.14, pursuant to the terms of the Series A-1 Certificate of Designation and subject to applicable beneficial ownership limitations."}],"balance_after":166,"derivative":{"exercise_price":0.0001,"exercise_date":"2026-08-24","underlying":"Series A-1 Preferred Stock","underlying_shares":166},"source":{"system":"sec-edgar","filing":"0001352620-26-000006","document":"wk-form4_1787782098.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000006/wk-form4_1787782098.xml","form_type":"4"}},{"id":749460,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2026-06-04T22:30:12.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":35000,"derivative":{"exercise_price":8.77,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-257901","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526257901/ownership.xml","form_type":"4"}},{"id":832264,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":43500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":43500,"derivative":{"exercise_price":0.45,"expiration_date":"2029-03-25","underlying":"Common Stock","underlying_shares":43500},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832263,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":47000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":47000,"derivative":{"exercise_price":0.45,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832262,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":325000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":325000,"derivative":{"exercise_price":0.45,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832261,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":650000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":650000,"derivative":{"exercise_price":0.45,"expiration_date":"2032-01-05","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832260,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":544500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":544500,"derivative":{"exercise_price":0.45,"expiration_date":"2032-12-06","underlying":"Common Stock","underlying_shares":544500},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832259,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":544500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":544500,"derivative":{"exercise_price":0.45,"expiration_date":"2033-03-19","underlying":"Common Stock","underlying_shares":544500},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832258,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":437500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":437500,"derivative":{"exercise_price":0.45,"expiration_date":"2033-11-19","underlying":"Common Stock","underlying_shares":437500},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832257,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":1312500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":1312500,"derivative":{"exercise_price":0.45,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":1312500},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832256,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":1540000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":1540000,"derivative":{"exercise_price":0.45,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":1540000},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832255,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":1680000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":1680000,"derivative":{"exercise_price":0.45,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":1680000},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832254,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":43500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":22.1,"expiration_date":"2029-03-25","underlying":"Common Stock","underlying_shares":43500},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832253,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":47000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":12.1,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832252,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":325000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":9.79,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832251,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":650000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":11.94,"expiration_date":"2032-01-05","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832250,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":544500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":2.16,"expiration_date":"2032-12-06","underlying":"Common Stock","underlying_shares":544500},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832249,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":544500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":1.21,"expiration_date":"2033-03-19","underlying":"Common Stock","underlying_shares":544500},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832248,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":437500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":0.838,"expiration_date":"2033-11-19","underlying":"Common Stock","underlying_shares":437500},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832247,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1312500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":0.97,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":1312500},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832246,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1540000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":1.13,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":1540000},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":832245,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:17:44.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1680000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Effective as of March 19, 2026 (the \"Repricing Date\"), the Issuer approved a one-time repricing of certain outstanding stock options (the \"Repriced Options\") granted under the Issuer's 2019 Incentive Award Plan (the \"2019 Plan\"), which reduced the per share exercise price of each Repriced Option to $0.45 (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":2.88,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":1680000},"source":{"system":"sec-edgar","filing":"0001352620-26-000004","document":"wk-form4_1774037861.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000004/wk-form4_1774037861.xml","form_type":"4"}},{"id":950839,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:40:16.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":1680000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of shares subject to the option will vest on January 2, 2027 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":1680000,"derivative":{"exercise_price":2.88,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":1680000},"source":{"system":"sec-edgar","filing":"0001352620-26-000002","document":"wk-form4_1767649212.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000002/wk-form4_1767649212.xml","form_type":"4"}},{"id":950838,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-05T21:40:16.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award, which will vest in four equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date."}],"balance_after":837793,"source":{"system":"sec-edgar","filing":"0001352620-26-000002","document":"wk-form4_1767649212.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262026000002/wk-form4_1767649212.xml","form_type":"4"}},{"id":974358,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T21:05:03.000Z","date":"2025-12-09","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":10.9764,"value":109764.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $10.60 to $11.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":23983,"source":{"system":"sec-edgar","filing":"0001193125-25-314154","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312525314154/ownership.xml","form_type":"4"}},{"id":974357,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-10T21:05:03.000Z","date":"2025-12-09","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":3.12,"value":31200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025."}],"balance_after":33983,"source":{"system":"sec-edgar","filing":"0001193125-25-314154","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312525314154/ownership.xml","form_type":"4"}},{"id":1026904,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-10-02T20:13:18.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":437500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents performance stock unit award, which will vest in full upon the earlier of (i) the approval of a new drug application for seralutinib or (ii) a change in control, in either case on or prior to the fourth anniversary of the grant date, and subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":557793,"source":{"system":"sec-edgar","filing":"0001352620-25-000004","document":"wk-form4_1759435995.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000135262025000004/wk-form4_1759435995.xml","form_type":"4"}},{"id":1119467,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2025-06-06T20:05:11.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":28500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":28500,"derivative":{"exercise_price":6.57,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":28500},"source":{"system":"sec-edgar","filing":"0000950170-25-083039","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017025083039/ownership.xml","form_type":"4"}},{"id":1193328,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-24T20:33:39.000Z","date":"2025-03-21","kind":"sale","planned":false,"acquired":false,"shares":22682,"price":8,"value":181456.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 20, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $8.00 to $8.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":23983,"source":{"system":"sec-edgar","filing":"0000950170-25-043903","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017025043903/ownership.xml","form_type":"4"}},{"id":1193327,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-24T20:33:39.000Z","date":"2025-03-21","kind":"exercise","planned":false,"acquired":true,"shares":22682,"price":6.32,"value":143350.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 20, 2024."}],"balance_after":46665,"source":{"system":"sec-edgar","filing":"0000950170-25-043903","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017025043903/ownership.xml","form_type":"4"}},{"id":1219342,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-06T21:03:10.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":1540000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares subject to the option will vest on March 4, 2026 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":1540000,"derivative":{"exercise_price":1.13,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":1540000},"source":{"system":"sec-edgar","filing":"0001728117-25-000008","document":"wk-form4_1741294981.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811725000008/wk-form4_1741294981.xml","form_type":"4"}},{"id":1470559,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-06-24T21:52:18.000Z","date":"2024-06-21","kind":"purchase","planned":false,"acquired":true,"shares":372000,"price":0.6728,"value":250281.6,"ownership":{"direct":false,"nature":"By family trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 23,172 shares, with the Reporting Person's sale of 23,172 shares of common stock at a price of $1.1554 per share on March 27, 2024. The Reporting Person paid to the Issuer $11,349.86, representing the full amount of the profit realized in connection with the short-swing transaction."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $0.6079 to $0.7217 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."}],"balance_after":5408073,"source":{"system":"sec-edgar","filing":"0001728117-24-000076","document":"wk-form4_1719265930.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811724000076/wk-form4_1719265930.xml","form_type":"4"}},{"id":1486603,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2024-06-07T20:30:03.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":26000,"derivative":{"exercise_price":21.79,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0000950170-24-070707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017024070707/ownership.xml","form_type":"4"}},{"id":1558291,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-03-28T22:01:45.000Z","date":"2024-03-27","kind":"sale","planned":false,"acquired":false,"shares":23172,"price":1.1554,"value":26772.9288,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $1.1603 to $1.1551 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."}],"balance_after":120293,"source":{"system":"sec-edgar","filing":"0001728117-24-000037","document":"wk-form4_1711663290.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811724000037/wk-form4_1711663290.xml","form_type":"4"}},{"id":1672904,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true}}],"security":"Option to Purchase Common Stock","published_at":"2024-01-24T01:37:49.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":49.2,"expiration_date":"2028-07-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001140361-24-003533","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000114036124003533/form4.xml","form_type":"4"}},{"id":1672903,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true}}],"security":"Option to Purchase Common Stock","published_at":"2024-01-24T01:37:49.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10716,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":45.66,"expiration_date":"2033-01-20","underlying":"Common Stock","underlying_shares":10716},"source":{"system":"sec-edgar","filing":"0001140361-24-003533","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000114036124003533/form4.xml","form_type":"4"}},{"id":1672902,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true}}],"security":"Option to Purchase Common Stock","published_at":"2024-01-24T01:37:49.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a \"Company Option\") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":4.35,"expiration_date":"2027-04-30","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001140361-24-003533","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000114036124003533/form4.xml","form_type":"4"}},{"id":1672901,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-01-24T01:37:49.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9702,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the \"Converted Cash Award\"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-003533","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000114036124003533/form4.xml","form_type":"4"}},{"id":1672900,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-01-24T01:37:49.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units (\"RSUs\") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU."}],"balance_after":9702,"source":{"system":"sec-edgar","filing":"0001140361-24-003533","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000114036124003533/form4.xml","form_type":"4"}},{"id":1672899,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-01-24T01:37:49.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8717,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company (\"BMS\"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of January 23, 2024 (such date and time of such Merger, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each issued and outstanding share of common stock of the Issuer (\"Company Common Stock\") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the \"Closing Consideration\") and (B) one contingent value right (a \"CVR\"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the \"Merger Consideration\"), without interest and subject to any withholding taxes."}],"balance_after":16035,"source":{"system":"sec-edgar","filing":"0001140361-24-003533","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000114036124003533/form4.xml","form_type":"4"}},{"id":1687498,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-04T22:00:56.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":1312500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares subject to the option will vest on January 2, 2025 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":1312500,"derivative":{"exercise_price":0.97,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":1312500},"source":{"system":"sec-edgar","filing":"0001728117-24-000002","document":"wk-form4_1704405629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811724000002/wk-form4_1704405629.xml","form_type":"4"}},{"id":1691690,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-03T23:18:25.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":9702,"price":58.75,"value":569992.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date."}],"balance_after":24752,"source":{"system":"sec-edgar","filing":"0001628280-24-000294","document":"wk-form4_1704323893.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000162828024000294/wk-form4_1704323893.xml","form_type":"4"}},{"id":1731012,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-23T00:07:15.000Z","date":"2023-11-20","kind":"grant","planned":false,"acquired":true,"shares":437500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares subject to the option will vest on November 20, 2024 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":437500,"derivative":{"exercise_price":0.838,"expiration_date":"2033-11-19","underlying":"Common Stock","underlying_shares":437500},"source":{"system":"sec-edgar","filing":"0001728117-23-000145","document":"wk-form4_1700698023.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811723000145/wk-form4_1700698023.xml","form_type":"4"}},{"id":1808437,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-14T20:41:20.000Z","date":"2023-08-11","kind":"purchase","planned":false,"acquired":true,"shares":10791,"price":27.8,"value":299989.8,"ownership":{"direct":false,"nature":"By Hasnain Revocable Trust Dated 2-19-2010"},"balance_after":10791,"source":{"system":"sec-edgar","filing":"0001209191-23-045653","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000120919123045653/doc4.xml","form_type":"4"}},{"id":1822757,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock Purchase Warrants","published_at":"2023-07-26T20:02:37.000Z","date":"2023-07-24","kind":"grant","planned":false,"acquired":true,"shares":135044,"price":0.125,"value":16880.5,"ownership":{"direct":false,"nature":"By family trust"},"balance_after":135044,"derivative":{"exercise_price":2.04,"exercise_date":"2023-07-24","expiration_date":"2028-07-24","underlying":"Common Stock","underlying_shares":135044},"source":{"system":"sec-edgar","filing":"0001728117-23-000099","document":"wf-form4_169040174487113.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811723000099/wf-form4_169040174487113.xml","form_type":"4"}},{"id":1822756,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-07-26T20:02:37.000Z","date":"2023-07-24","kind":"grant","planned":false,"acquired":true,"shares":540176,"price":1.82,"value":983120.32,"ownership":{"direct":false,"nature":"By family trust"},"balance_after":5036073,"source":{"system":"sec-edgar","filing":"0001728117-23-000099","document":"wf-form4_169040174487113.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811723000099/wf-form4_169040174487113.xml","form_type":"4"}},{"id":1869494,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2023-06-02T20:49:43.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":26000,"derivative":{"exercise_price":13.32,"expiration_date":"2033-05-30","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001209191-23-033850","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919123033850/doc4.xml","form_type":"4"}},{"id":1899368,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-09T20:12:34.000Z","date":"2023-05-05","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shall vest and become exercisable as follows: (i) with respect to 50% of the shares subject to the option,  the Issuer's common stock achieving a 30-day average stock price at or above $5 per share within four years of the grant date; (ii) with respect to 25% of the shares subject to the option, the Issuer's common stock achieving a 30-day average stock price at or above $7.50 per share within four years of the grant date; and (iii) with respect to the remaining 25% of the shares subject to the option, the Issuer's common stock achieving a 30-day average stock price at or above $10 per share within four years of the grant date; in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date; provided in no event will any portion of the option vest prior to the first anniversary of the grant date."}],"balance_after":750000,"derivative":{"exercise_price":1.36,"expiration_date":"2033-05-04","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001728117-23-000052","document":"wf-form4_168366312804581.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811723000052/wf-form4_168366312804581.xml","form_type":"4"}},{"id":1941501,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-22T21:14:52.000Z","date":"2023-03-20","kind":"grant","planned":false,"acquired":true,"shares":544500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the total number of shares subject to the option will vest on March 20, 2024 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":544500,"derivative":{"exercise_price":1.21,"expiration_date":"2033-03-19","underlying":"Common Stock","underlying_shares":544500},"source":{"system":"sec-edgar","filing":"0001728117-23-000018","document":"wf-form4_167951967938039.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811723000018/wf-form4_167951967938039.xml","form_type":"4"}},{"id":1941500,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-03-22T21:14:52.000Z","date":"2023-03-22","kind":"purchase","planned":false,"acquired":true,"shares":440500,"price":1.1432,"value":503579.6,"ownership":{"direct":false,"nature":"By family trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $1.06 to $1.20 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."}],"balance_after":4495897,"source":{"system":"sec-edgar","filing":"0001728117-23-000018","document":"wf-form4_167951967938039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811723000018/wf-form4_167951967938039.xml","form_type":"4"}},{"id":1941499,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-03-22T21:14:52.000Z","date":"2023-03-21","kind":"purchase","planned":false,"acquired":true,"shares":269389,"price":1.1965,"value":322323.9385,"ownership":{"direct":false,"nature":"By family trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $1.155 to $1.21 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."}],"balance_after":4055397,"source":{"system":"sec-edgar","filing":"0001728117-23-000018","document":"wf-form4_167951967938039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811723000018/wf-form4_167951967938039.xml","form_type":"4"}},{"id":1941498,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2023-03-22T21:14:52.000Z","date":"2023-03-20","kind":"purchase","planned":false,"acquired":true,"shares":168683,"price":1.0344,"value":174485.6952,"ownership":{"direct":false,"nature":"By family trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $0.97 to 1.09 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."}],"balance_after":3786008,"source":{"system":"sec-edgar","filing":"0001728117-23-000018","document":"wf-form4_167951967938039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811723000018/wf-form4_167951967938039.xml","form_type":"4"}},{"id":2047376,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non Qualified Stock Option (right to buy)","published_at":"2023-01-24T21:17:41.000Z","date":"2023-01-20","kind":"grant","acquired":true,"shares":10716,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":10716,"derivative":{"exercise_price":45.66,"expiration_date":"2033-01-20","underlying":"Common Stock","underlying_shares":10716},"source":{"system":"sec-edgar","filing":"0001214659-23-001046","document":"marketforms-58255.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000121465923001046/marketforms-58255.xml","form_type":"4"}},{"id":2047375,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-24T21:17:41.000Z","date":"2023-01-20","kind":"grant","acquired":true,"shares":6333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs).  Shares will vest 100% on the anniversary of the grant date."}],"balance_after":15050,"source":{"system":"sec-edgar","filing":"0001214659-23-001046","document":"marketforms-58255.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000121465923001046/marketforms-58255.xml","form_type":"4"}},{"id":2091033,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-09T22:13:40.000Z","date":"2022-12-07","kind":"grant","acquired":true,"shares":544500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total number of shares subject to the option will vest on December 7, 2023 and 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":544500,"derivative":{"exercise_price":2.16,"expiration_date":"2032-12-06","underlying":"Common Stock","underlying_shares":544500},"source":{"system":"sec-edgar","filing":"0001728117-22-000104","document":"wf-form4_167062400607119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811722000104/wf-form4_167062400607119.xml","form_type":"4"}},{"id":2206968,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-07-15T20:21:19.000Z","date":"2022-07-15","kind":"purchase","acquired":true,"shares":138696,"price":7.21,"value":999998.16,"ownership":{"direct":false,"nature":"By family trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 19,035 shares, with the Reporting Person's sale of 19,035 shares of common stock at a price of $8.915 per share on March 23, 2022. The Reporting Person paid to the Issuer $32,454.68, representing the full amount of the profit realized in connection with the short-swing transaction."}],"balance_after":3617325,"source":{"system":"sec-edgar","filing":"0001728117-22-000059","document":"wf-form4_165791646217786.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811722000059/wf-form4_165791646217786.xml","form_type":"4"}},{"id":2222961,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2022-06-23T20:44:33.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":14.84,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001209191-22-038913","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919122038913/doc4.xml","form_type":"4"}},{"id":2318867,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2022-03-24T20:55:36.000Z","date":"2022-03-23","kind":"sale","acquired":false,"shares":19035,"price":8.915,"value":169697.025,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":143465,"source":{"system":"sec-edgar","filing":"0001728117-22-000031","document":"wf-form4_164815532088964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811722000031/wf-form4_164815532088964.xml","form_type":"4"}},{"id":2433593,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non Qualified Stock Option (right to buy)","published_at":"2022-01-19T01:32:26.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":5243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":5243,"derivative":{"exercise_price":124.31,"expiration_date":"2032-01-13","underlying":"Common Stock","underlying_shares":5243},"source":{"system":"sec-edgar","filing":"0001214659-22-000854","document":"marketforms-55085.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000121465922000854/marketforms-55085.xml","form_type":"4"}},{"id":2433592,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-19T01:32:26.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":3619,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs).  Shares will vest 100% on the anniversary of the grant date."}],"balance_after":8717,"source":{"system":"sec-edgar","filing":"0001214659-22-000854","document":"marketforms-55085.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000121465922000854/marketforms-55085.xml","form_type":"4"}},{"id":2438817,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-10T21:03:01.000Z","date":"2022-01-06","kind":"grant","acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the total number of shares subject to the option will vest on January 6, 2023 and 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":650000,"derivative":{"exercise_price":11.94,"expiration_date":"2032-01-05","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001728117-22-000002","document":"wf-form4_164184855665829.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811722000002/wf-form4_164184855665829.xml","form_type":"4"}},{"id":2657002,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2021-06-23T21:15:21.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":21.54,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001209191-21-042779","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919121042779/doc4.xml","form_type":"4"}},{"id":2825957,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-02T00:40:10.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the total number of shares subject to the option will vest on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":325000,"derivative":{"exercise_price":9.79,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001728117-21-000027","document":"wf-form4_161464558623631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811721000027/wf-form4_161464558623631.xml","form_type":"4"}},{"id":2825956,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-03-02T00:40:10.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":162500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date."}],"balance_after":162500,"source":{"system":"sec-edgar","filing":"0001728117-21-000027","document":"wf-form4_161464558623631.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000172811721000027/wf-form4_161464558623631.xml","form_type":"4"}},{"id":2829980,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock","published_at":"2021-02-27T00:00:28.000Z","date":"2021-02-10","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. (\"Panacea\"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea (\"Merger Sub\"), and Nuvation Bio Inc. (\"Legacy Nuvation\") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the \"Business Combination\"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. (\"Panacea\"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea (\"Merger Sub\"), and Nuvation Bio Inc. (\"Legacy Nuvation\") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the \"Business Combination\"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. (\"Panacea\"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea (\"Merger Sub\"), and Nuvation Bio Inc. (\"Legacy Nuvation\") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the \"Business Combination\"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001213900-21-012230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000121390021012230/ownership.xml","form_type":"4"}},{"id":2829979,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-02-27T00:00:28.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":30000,"price":10,"value":300000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share."}],"balance_after":55000,"source":{"system":"sec-edgar","filing":"0001213900-21-012230","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000121390021012230/ownership.xml","form_type":"4"}},{"id":2829978,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-02-27T00:00:28.000Z","date":"2021-02-10","kind":"exercise","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. (\"Panacea\"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea (\"Merger Sub\"), and Nuvation Bio Inc. (\"Legacy Nuvation\") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the \"Business Combination\"), was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001213900-21-012230","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000121390021012230/ownership.xml","form_type":"4"}},{"id":2902044,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non Qualified Stock Option (right to buy)","published_at":"2021-01-20T23:14:52.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":3064,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":3064,"derivative":{"exercise_price":214.47,"expiration_date":"2031-01-14","underlying":"Common Stock","underlying_shares":3064},"source":{"system":"sec-edgar","filing":"0001214659-21-000674","document":"marketforms-50983.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000121465921000674/marketforms-50983.xml","form_type":"4"}},{"id":2902043,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-20T23:14:52.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":2098,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs).  Shares will vest 100% on the anniversary of the grant date."}],"balance_after":5098,"source":{"system":"sec-edgar","filing":"0001214659-21-000674","document":"marketforms-50983.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000121465921000674/marketforms-50983.xml","form_type":"4"}},{"id":3007087,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-14T23:28:37.000Z","date":"2020-10-14","kind":"purchase","acquired":true,"shares":96520,"price":10.3605,"value":999995.46,"ownership":{"direct":false,"nature":"By family trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $10.00 to $10.55 per share. The price reported above reflects the weighted average sale price for the entire number of shares purchased. Information on the exact number of shares purchased at each sale price can be obtained from the Issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,491,103 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreements between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on January 4, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":3478629,"source":{"system":"sec-edgar","filing":"0001209191-20-054841","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000120919120054841/doc4.xml","form_type":"4"}},{"id":3098413,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2020-06-26T20:07:18.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":23000,"derivative":{"exercise_price":17.97,"expiration_date":"2030-06-23","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0001209191-20-039068","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919120039068/doc4.xml","form_type":"4"}},{"id":3105322,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-18T20:51:04.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":47000,"derivative":{"exercise_price":12.1,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001209191-20-037633","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000120919120037633/doc4.xml","form_type":"4"}},{"id":3316171,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non Qualified Stock Option (right to buy)","published_at":"2020-01-08T01:29:16.000Z","date":"2020-01-03","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant."}],"balance_after":6000,"derivative":{"exercise_price":113.2,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001214659-20-000195","document":"marketforms-47233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000121465920000195/marketforms-47233.xml","form_type":"4"}},{"id":3316170,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-08T01:29:16.000Z","date":"2020-01-03","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (RSUs).  Shares will vest 100% on the anniversary of the grant date."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001214659-20-000195","document":"marketforms-47233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000121465920000195/marketforms-47233.xml","form_type":"4"}},{"id":3397259,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-10-05T00:22:03.000Z","date":"2019-10-04","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019."}],"balance_after":7500,"derivative":{"exercise_price":0.6391,"expiration_date":"2029-10-03","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-19-052615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120919119052615/doc4.xml","form_type":"4"}},{"id":3405157,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-27T14:41:21.000Z","date":"2019-09-27","kind":"purchase","acquired":true,"shares":10000,"price":16.798,"value":167980.0,"ownership":{"direct":false,"nature":"By family trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $16.25 to $17.47 per share. The price reported above reflects the weighted average sale price for the entire number of shares purchased. Information on the exact number of shares purchased at each sale price can be obtained from the Issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,209,015 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreements between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on January 4, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date."}],"balance_after":3382109,"source":{"system":"sec-edgar","filing":"0001209191-19-050928","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000120919119050928/doc4.xml","form_type":"4"}},{"id":3476847,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2019-06-27T20:06:41.000Z","date":"2019-06-25","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":13000,"derivative":{"exercise_price":19.55,"expiration_date":"2029-06-24","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001209191-19-039241","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919119039241/doc4.xml","form_type":"4"}},{"id":3504530,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-03T20:11:54.000Z","date":"2019-05-30","kind":"purchase","acquired":true,"shares":250,"price":5.1495,"value":1287.375,"ownership":{"direct":false,"nature":"By Faheem Hasnain and Marie Hasnain Co-Trustees of the Hasnain Revocable Trust,dtd February 19, 2010"},"balance_after":245857,"source":{"system":"sec-edgar","filing":"0001209191-19-033882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120919119033882/doc4.xml","form_type":"4"}},{"id":3504529,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-03T20:11:54.000Z","date":"2019-05-30","kind":"purchase","acquired":true,"shares":3890,"price":5.299,"value":20613.11,"ownership":{"direct":false,"nature":"By Faheem Hasnain and Marie Hasnain Co-Trustees of the Hasnain Revocable Trust,dtd February 19, 2010"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average purchase price for the transaction reported was $5.2990, and the range of prices were between $5.29 and $5.30. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":245607,"source":{"system":"sec-edgar","filing":"0001209191-19-033882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120919119033882/doc4.xml","form_type":"4"}},{"id":3504528,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-03T20:11:54.000Z","date":"2019-05-30","kind":"purchase","acquired":true,"shares":38860,"price":4.5912,"value":178414.032,"ownership":{"direct":false,"nature":"By Faheem Hasnain and Marie Hasnain Co-Trustees of the Hasnain Revocable Trust,dtd February 19, 2010"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $4.5912, and the range of prices were between $4.22 and $5.00. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":241717,"source":{"system":"sec-edgar","filing":"0001209191-19-033882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120919119033882/doc4.xml","form_type":"4"}},{"id":3506198,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-05-31T20:20:36.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 monthly installments following the date of grant."}],"balance_after":20000,"derivative":{"exercise_price":4.22,"expiration_date":"2029-05-28","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-19-033652","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120919119033652/doc4.xml","form_type":"4"}},{"id":3578305,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-26T22:35:15.000Z","date":"2019-03-25","kind":"grant","acquired":true,"shares":43500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares subject to the option will vest on March 25, 2020 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date."}],"balance_after":43500,"derivative":{"exercise_price":22.1,"expiration_date":"2029-03-25","underlying":"Common Stock","underlying_shares":43500},"source":{"system":"sec-edgar","filing":"0001209191-19-021358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000120919119021358/doc4.xml","form_type":"4"}},{"id":3645491,"issuer":{"id":94908,"kind":"organization","name":"Mirati Therapeutics, Inc.","symbol":"MRTX"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2019-02-20T22:05:14.000Z","date":"2019-02-15","kind":"grant","acquired":true,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the Option vest and become exercisable in 36 equal monthly installments following the date of grant."}],"balance_after":47000,"derivative":{"exercise_price":72.62,"expiration_date":"2029-02-14","underlying":"Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001214659-19-001392","document":"marketforms-44143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000121465919001392/marketforms-44143.xml","form_type":"4"}},{"id":3662840,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series B Preferred Stock","published_at":"2019-02-12T22:25:44.000Z","date":"2019-02-12","kind":"exercise","acquired":false,"shares":77719,"ownership":{"direct":false,"nature":"By family trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":17270},"source":{"system":"sec-edgar","filing":"0001209191-19-009410","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000120919119009410/doc4.xml","form_type":"4"}},{"id":3662839,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series A Preferred Stock","published_at":"2019-02-12T22:25:44.000Z","date":"2019-02-12","kind":"exercise","acquired":false,"shares":185984,"ownership":{"direct":false,"nature":"By family trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":41329},"source":{"system":"sec-edgar","filing":"0001209191-19-009410","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000120919119009410/doc4.xml","form_type":"4"}},{"id":3662838,"issuer":{"id":6928,"kind":"organization","name":"Gossamer Bio, Inc.","symbol":"GOSS"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2019-02-12T22:25:44.000Z","date":"2019-02-12","kind":"exercise","acquired":true,"shares":58599,"ownership":{"direct":false,"nature":"By family trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 4.5 to one share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,595,584 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreements between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on January 4, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. The shares are also subject to certain accelerated vesting provisions as set forth in more detail in the employment agreement between the Issuer and the Reporting Person."}],"balance_after":3372109,"source":{"system":"sec-edgar","filing":"0001209191-19-009410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000120919119009410/doc4.xml","form_type":"4"}},{"id":3814147,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-09-18T01:26:07.000Z","date":"2018-09-13","kind":"sale","acquired":false,"shares":118243,"price":0.4378,"value":51766.7854,"ownership":{"direct":true},"balance_after":4500,"source":{"system":"sec-edgar","filing":"0001280776-18-000088","document":"wf-form4_153723394976637.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000128077618000088/wf-form4_153723394976637.xml","form_type":"4"}},{"id":3814146,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-09-18T01:26:07.000Z","date":"2018-09-13","kind":"sale","acquired":false,"shares":59200,"price":0.4377,"value":25911.84,"ownership":{"direct":true},"balance_after":122743,"source":{"system":"sec-edgar","filing":"0001280776-18-000088","document":"wf-form4_153723394976637.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000128077618000088/wf-form4_153723394976637.xml","form_type":"4"}},{"id":3883997,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2018-06-25T20:43:09.000Z","date":"2018-06-21","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 monthly installments following the date of grant."}],"balance_after":20000,"derivative":{"exercise_price":8.98,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-18-039408","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120919118039408/doc4.xml","form_type":"4"}},{"id":3899904,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2018-06-08T20:10:06.000Z","date":"2018-06-07","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":13000,"derivative":{"exercise_price":16.35,"expiration_date":"2028-06-06","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001209191-18-036659","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919118036659/doc4.xml","form_type":"4"}},{"id":3916904,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-25T20:09:42.000Z","date":"2018-05-23","kind":"grant","acquired":true,"shares":41353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders."}],"balance_after":41353,"derivative":{"exercise_price":6.1,"expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":41353},"source":{"system":"sec-edgar","filing":"0001280776-18-000045","document":"wf-form4_152727896677922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000128077618000045/wf-form4_152727896677922.xml","form_type":"4"}},{"id":4208268,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-15T20:19:17.000Z","date":"2017-09-14","kind":"purchase","acquired":true,"shares":59200,"price":4.187,"value":247870.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.925 to $4.45. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in this footnote (1) to this Form 4."}],"balance_after":181943,"source":{"system":"sec-edgar","filing":"0001280776-17-000092","document":"wf-form4_150550674325248.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000128077617000092/wf-form4_150550674325248.xml","form_type":"4"}},{"id":4215821,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-09-06T20:10:31.000Z","date":"2017-09-05","kind":"grant","acquired":true,"shares":15222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary from September 5, 2017 or the day prior to the Company's 2018 annual meeting of stockholders."}],"balance_after":15222,"derivative":{"exercise_price":3.15,"expiration_date":"2027-09-04","underlying":"Common Stock","underlying_shares":15222},"source":{"system":"sec-edgar","filing":"0001280776-17-000084","document":"wf-form4_150472861787568.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000128077617000084/wf-form4_150472861787568.xml","form_type":"4"}},{"id":4285445,"issuer":{"id":4871,"kind":"organization","name":"Kura Oncology, Inc.","symbol":"KURA"},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase common stock","published_at":"2017-06-12T21:50:39.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the one year anniversary of the date of grant."}],"balance_after":10000,"derivative":{"exercise_price":8.6,"expiration_date":"2027-06-08","underlying":"Common stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-039258","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422143/000120919117039258/doc4.xml","form_type":"4"}},{"id":4304592,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-05-25T21:34:42.000Z","date":"2017-05-23","kind":"grant","acquired":true,"shares":45022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary from May 23, 2017 or the day prior to the Company's 2018 annual meeting of stockholders."}],"balance_after":45022,"derivative":{"exercise_price":3.2,"expiration_date":"2027-05-22","underlying":"Common Stock","underlying_shares":45022},"source":{"system":"sec-edgar","filing":"0001280776-17-000049","document":"wf-form4_149574806715383.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1352620/000128077617000049/wf-form4_149574806715383.xml","form_type":"4"}},{"id":4347406,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-04-21T21:28:24.000Z","date":"2017-04-19","kind":"purchase","acquired":true,"shares":100000,"price":10,"value":1000000.0,"ownership":{"direct":false,"nature":"By Faheem Hasnain and Marie Hasnain Co-Trustees of the Hasnain Revocable Trust,dtd February 19, 2010"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were purchased at the Issuer's initial public offering."}],"balance_after":202857,"source":{"system":"sec-edgar","filing":"0001209191-17-027904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120919117027904/doc4.xml","form_type":"4"}},{"id":4347405,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-04-21T21:28:24.000Z","date":"2017-04-19","kind":"other","acquired":true,"shares":102857,"price":10,"value":1028570.0,"ownership":{"direct":false,"nature":"By Faheem Hasnain and Marie Hasnain Co-Trustees of the Hasnain Revocable Trust,dtd February 19, 2010"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the conversion of an outstanding convertible promissory note in the principal amount of $1,000,000, plus $28,575.34 accrued interest, into shares of the Issuer's common stock upon closing of the Issuer's initial public offering at a conversion price of $10.00 per share."}],"balance_after":102857,"source":{"system":"sec-edgar","filing":"0001209191-17-027904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120919117027904/doc4.xml","form_type":"4"}},{"id":4353409,"issuer":{"id":9529,"kind":"organization","name":"Forte Biosciences, Inc."},"owners":[{"id":19447,"kind":"person","name":"Hasnain Faheem","position":1,"cik":"0001352620","reported_name":"Hasnain Faheem","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-04-13T01:02:52.000Z","date":"2017-04-12","kind":"grant","acquired":true,"shares":10869,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares vest one year after 4/1/2017; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 4/1/2017."}],"balance_after":10869,"derivative":{"exercise_price":10,"expiration_date":"2027-04-11","underlying":"Common Stock","underlying_shares":10869},"source":{"system":"sec-edgar","filing":"0001209191-17-026752","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1419041/000120919117026752/doc4.xml","form_type":"4"}}]}